SCHEMBL9890648

SCHEMBL9890648

COc1ccc(-c2ccccc2)c(CC(=O)O)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.62
PTGS1 P23219 2/20 0.51
MMP2 P08253 4/20 0.50
MMP12 P39900 4/20 0.50
KDM4E B2RXH2 3/20 0.50
MMP9 P14780 3/20 0.50
BACE1 P56817 2/20 0.50
AKR1C3 P42330 1/20 0.50
AKR1C2 P52895 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
ABL1 P00519 1/20 0.50
POLB P06746 1/20 0.50
MAPT P10636 1/20 0.50
RECQL P46063 1/20 0.50
RIN1 Q13671 1/20 0.50
CTDSP1 Q9GZU7 1/20 0.50
MMP8 P22894 3/20 0.49
MMP13 P45452 3/20 0.49
MMP14 P50281 3/20 0.49
MMP16 P51512 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3738351 0.92 HSD17B10 (0.64) HSD17B10PTGS1MMP2MMP12KDM4E
SCHEMBL3735319 0.88 HSD17B10 (0.59) HSD17B10PTGS1MMP2MMP12KDM4E
SCHEMBL9890726 0.88 PLA2G10 (0.52) HSD17B10KDM4EBACE1SMN1; SMN2MAPT
SCHEMBL11889771 0.87 HSD17B10 (0.55) HSD17B10MMP2MMP12KDM4EMMP9
SCHEMBL3736235 0.87 HSD17B10 (0.57) HSD17B10PTGS1KDM4EAKR1C3AKR1C2
SCHEMBL3738751 0.87 HSD17B10 (0.57) HSD17B10PTGS1MMP2MMP12KDM4E
SCHEMBL3737508 0.86 CYP11B2 (0.55) HSD17B10KDM4E
SCHEMBL4961133 0.83 PTPN1 (0.50) KDM4EBACE1SMN1; SMN2MAPTTAS1R3
SCHEMBL27821291 0.83 BAZ2B (0.53) HSD17B10KDM4EBACE1SMN1; SMN2MAPT
SCHEMBL5235960 0.83 HSD17B10 (0.54) HSD17B10PTGS1MMP2MMP12KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 HSD17B10 1303/4885PTGS1 2007/4885MMP2 1085/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 HSD17B10 1303/4885PTGS1 2007/4885MMP2 1085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.